NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced the United States Food and Drug Administration approved Retacrit orepoetin alfa-epbx, a biosimilar to Epogen and Procrit (epoetin alfa), for a...
Original Article: Pfizer: FDA Oks First Epoetin Alfa Biosimilar For Treatment Of Anemia